Predicting the perceptual experience of retinal prosthesis patients for Retinitis Pigmentosa

N/A

Waitlist Available

Led By Michael Beyeler, PhD

Research Sponsored by University of California, Santa Barbara

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through study completion, an average of 1 year

Awards & highlights

No Placebo-Only Group

Summary

This trial aims to improve the Argus II device, which helps people with severe vision loss see by sending electrical signals to their eyes. The study focuses on patients with retinal diseases and seeks to make their vision clearer by developing better signal-sending methods. The Argus II device was developed to restore some vision to patients blind due to specific retinal conditions and has been tested for many years.

Eligible Conditions

Retinitis Pigmentosa
Blindness

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through study completion, an average of 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through study completion, an average of 1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and through study completion, an average of 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Pattern discrimination accuracy

Phosphene brightness relative to reference stimulus

Phosphene shape

+1 more

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups

Experimental Treatment

Group I: Predicting the perceptual experience of retinal prosthesis patientsExperimental Treatment1 Intervention

This intervention will assess the effect of different stimulation strategies on the perceptual experience of retinal prosthesis patients. We will produce visual percepts in patients either by directly stimulating electrodes (using FDA-approved pulse trains) or by asking them to view a computer or projector screen and using standard FDA-approved stimulation protocols (as is standardly used for their devices) to convert the computer or projector screen image into pulse trains on their electrodes. Existing blind users of the Argus II will be recruited for this study. Performance of Argus II users will be compared to performance of sighted subjects viewing a prosthetic vision simulation in virtual reality.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Argus II

2022

N/A

~70

Do I qualify?Apply below to find out